Core Viewpoint - The stock market experienced fluctuations, particularly in the pharmaceutical sector, but the company's fundamentals and long-term industry trends remain positive [1][2] Group 1: Stock Performance - On June 17, the Hong Kong stock market indices showed a downward trend, with the Hang Seng Index falling by 0.34%, the Hang Seng China Enterprises Index down by 0.4%, and the Hang Seng Tech Index decreasing by 0.15% [1] - Pharmaceutical stocks generally retreated, with the company, Yaoshi Bang (9885.HK), dropping by 6.31% to close at 10.4 HKD [1] Group 2: Company Actions - In response to stock price volatility, the company has been actively repurchasing shares and increasing executive holdings to stabilize market expectations [1] - On June 17, the company repurchased 100,000 shares at a total cost of approximately 1.03 million HKD, averaging 10.31 HKD per share [1] - Since initiating a billion HKD repurchase plan on May 7, the company has repurchased a total of 5.53 million shares, with a total repurchase amount exceeding 43.34 million HKD [1] - Executive Director Chen Fei also increased his holdings by 100,000 shares on June 17, bringing the total to over 900,000 shares, reflecting management's confidence in the company's future [1] Group 3: Financial Performance - The company has released positive signals this year, achieving its first annual profit in 2024, with a net profit of 157 million HKD, representing a year-on-year increase of 20.1% [1] - High-margin business growth has accelerated, with the transaction scale of the brand's first-push business reaching 717 million HKD from January to April, a year-on-year increase of 108.1% [1] - The company's proprietary brand business reached 560 million HKD, showing a significant year-on-year growth of 532.3%, indicating the formation of new growth momentum [1] Group 4: Industry Trends - The company is adapting to future pharmacy industry upgrades by entering the fields of pharmaceutical robotics and AI models [2] - In June, the company formed a strategic partnership with leading collaborative robotics firm, Yuejiang Technology, to explore high-value-added business opportunities in new retail scenarios through pharmaceutical collaborative robots, AI models, and drug IoT technologies [2] - Industry experts believe that the recent decline in the pharmaceutical sector is more related to technical adjustments following profit-taking rather than direct impacts from industrial policies or significant fundamental changes [2]

Core Viewpoint - After a strong two-month rally, the stock price of Yaoshi Bang (9885.HK) consolidated between HKD 10-11 from June 9 to June 11, following a year-to-date increase of over 120% and a market capitalization exceeding HKD 7 billion [1][2] Group 1: Company Performance - Yaoshi Bang is expected to achieve a full turnaround to profitability in 2024, with a projected adjusted net profit of HKD 157 million, representing a year-on-year increase of 20.1% [1] - The company’s high-margin business has accelerated growth, with a transaction scale of HKD 717 million in its brand promotion business from January to April, marking a year-on-year increase of 108.1% [1] - The company’s fundamentals have shown significant improvement, validating its profit logic [1] Group 2: Strategic Initiatives - On June 3, Yaoshi Bang entered into a strategic partnership with leading collaborative robot company Yujian Technology, focusing on integrating pharmaceutical collaborative robots, AI models, and drug IoT technologies into new retail scenarios [1] - This initiative aims to explore high-value-added business opportunities targeting retail pharmacies [1] Group 3: Market Sentiment and Analyst Ratings - The company’s quality attributes have attracted significant institutional interest, with Changcheng Securities and Tianfeng Securities both issuing "Buy" ratings, while Xinda Securities is more optimistic, projecting a compound annual growth rate of 145% for net profit from 2024 to 2027 [2] - The management has demonstrated confidence through actions, including a billion-dollar buyback plan initiated in May 2025, with 5.435 million shares repurchased for over HKD 42.31 million from May 7 to June 11 [2] - The Hong Kong pharmaceutical sector remains active, with multiple policy benefits being released, indicating a potential new market rally [2]